Gain Therapeutics (GANX) Short term Debt (2020 - 2026)

Gain Therapeutics has reported Short term Debt for 7 years, with the latest figure at $123628.0 in Q2 2026.

• On a quarterly basis, Short term Debt fell 1.97% year-over-year to $123628.0 in Q2 2026; TTM through Jun 2026 was $123628.0, a 1.97% decrease from a year earlier, with the FY2025 full-year figure at $100869.0, down 8.45% from the prior year.
• Short term Debt was $123628.0 for Q2 2026 at Gain Therapeutics, up from $100281.0 in the prior quarter.
• The five-year high for Short term Debt was $126108.0 in Q2 2025, with the low at $83747.0 in Q2 2022.
• Average Short term Debt over 5 years is $109366.0, with a median of $110512.5 recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Short term Debt jumped 95.6% in 2022, then fell 11.35% in 2026.
• Over 5 years, Short term Debt stood at $108135.0 in 2022, then climbed by 9.86% to $118797.0 in 2023, then fell by 7.26% to $110177.0 in 2024, then slipped by 8.45% to $100869.0 in 2025, then increased by 22.56% to $123628.0 in 2026.
• The last three Short term Debt figures came in at $123628.0 (Q2 2026), $100281.0 (Q1 2026), and $100869.0 (Q4 2025), per Business Quant data.